Related references
Note: Only part of the references are listed.Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
Juanjuan Yuan et al.
PROTEIN & CELL (2021)
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Lihong Peng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study
Aldo Bonaventura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of immunization against PCSK9 in an experimental model of breast cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Wieneke Dijk et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
Xiaohui Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Cholesterol metabolism: A review of how ageing disrupts the biological mechanisms responsible for its regulation
A. E. Morgan et al.
AGEING RESEARCH REVIEWS (2016)
PCSK9 Association With Lipoprotein(a)
Hagai Tavori et al.
CIRCULATION RESEARCH (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population
Marco Bertolotti et al.
CLINICAL INTERVENTIONS IN AGING (2014)
Lipoprotein(a) plasma levels and the risk of cancer: the PRIME study
Emilie Marrer et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2013)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Affects Gene Expression Pathways Beyond Cholesterol Metabolism in Liver Cells
Hong Lan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
